Deal validates DARPins

DARPins: a new generation of protein therapeutics.

DARPins (designed ankyrin repeat proteins) are a novel class of binding molecules with the potential to overcome limitations of monoclonal antibodies, hence allowing novel therapeutic approaches. DARPins are small, single domain proteins (14 kDa) which can be selected to bind any given target protein with high affinity and specificity. These characteristics make them ideal agonistic, antagonist...

Trial Validates Biosimilar for Trastuzumab.

Preliminary data from the phase III Heritage trial suggest that a biosimilar to trastuzumab, MYL-14010, is just as safe and effective as its brand-name equivalent for women with HER2-positive advanced breast cancer. The findings, presented during the annual meeting of the American Society of Clinical Oncology in June, may pave the way for the first FDA-approved biosimilar for cancer.

Big Deal - good deal? Or is there a better deal?

Deal or No Deal? - Asessing the Daily Deal Shopper

We build upon previous work done in online shopping segmentation but follow a customer-revealed approach by using an explorative cluster analysis on a sample of 11,848 daily deal shoppers located in Switzerland. We identify six segments into which the daily deal shoppers can be categorized: recreational shoppers, mobile shoppers, traditionalists, bargain hunters, socializers, and convenience se...

Whose experience validates what for Dharmakı̄rti?

It is well known that Dharmakı̄rti followed Dignāga in accepting that there are exactly two sources of new knowledge (pramān. a), namely, sensation (pratyaks. a) and inference (anumāna), and that the criteria by which these two means of acquiring knowledge are distinguished were somewhat different for the two philosophers. Dignāga claimed that the two sources of knowledge were distinct in that s...